Thread by @mchilberg

$BEAM 4Q20 results out. Valuation is crazy but they are the best of #Crispr breed in my opinion given execution to date.
#GeneTherapy
1/

$BEAM focus on platform, delivery and manufacturing is enabled by share price and ability to source funds without huge dilution
2/

$BEAM focus on based editing of transition mutations.
3/
#dreaminase

$BEAM is both in-licensing and out-licensing which makes sense given funding ability and fields of interest
4/

$BEAM ties to Broad and Harvard are more costly given valuation ties to agreements. Derivative liability increase in C20 show impacts.
5/

Feb $BEAM acquisition of Guide and private placement only drove 9% dilution. Nice to be able to extend runway by 1.5 years and bring in delivery capabilities for relatively low cost
6/6